Skip to main content
/ Nascholing / Video

Video’s

Toegang tot het hele platform? Registreer je vrijblijvend.

Amivantamab plus lazertinib is a new standard for EGFR-mutant NSCLC (MARIPOSA-2)
Amivantamab plus lazertinib is a new standard for EGFR-mutant NSCLC (MARIPOSA-2)Video

Amivantamab plus lazertinib is a new standard for EGFR-mutant NSCLC (MARIPOSA-2)

September 2024 For VJ Oncology Dr. Antonio Passaro, Italy, highlights recent updates regarding the treatment…
The clinical impact of amivantamab and chemotherapy in EGFRm NSCLC (MARIPOSA-2)
The clinical impact of amivantamab and chemotherapy in EGFRm NSCLC (MARIPOSA-2)Video

The clinical impact of amivantamab and chemotherapy in EGFRm NSCLC (MARIPOSA-2)

September 2024 For VJ Oncology Dr. Sanjay Popat explores the MARIPOSA-2 trial (NCT04487080), which demonstrated a…
PROs for telisotuzumab vedotin in c-Met overexpressing NSCLC (LUMINOSITY)
PROs for telisotuzumab vedotin in c-Met overexpressing NSCLC (LUMINOSITY)Video

PROs for telisotuzumab vedotin in c-Met overexpressing NSCLC (LUMINOSITY)

September 2024 https://www.youtube.com/embed/Xl52bXzhjek For VJ Oncology Dr. Nicolas Girard, France, discusses the findings from the…
SOHO-02: BAY 2927088, an oral HER2 TKI, for first-line NSCLC
SOHO-02: BAY 2927088, an oral HER2 TKI, for first-line NSCLCVideo

SOHO-02: BAY 2927088, an oral HER2 TKI, for first-line NSCLC

September 2024 For VJ Oncology Dr. Antonio Passaro, Italy, discusses the Phase I/II SOHO-02 trial…
Emerging role of ADCs in EGFR-mutated non-small cell lung cancer
Emerging role of ADCs in EGFR-mutated non-small cell lung cancerVideo

Emerging role of ADCs in EGFR-mutated non-small cell lung cancer

September 2024 For VJ Oncology Dr. Benjamin Besse, France, discusses the growing interest in antibody-drug…
Durvalumab as consolidation treatment for patients with limited-stage small cell lung cancer (ADRIATIC)
Durvalumab as consolidation treatment for patients with limited-stage small cell lung cancer (ADRIATIC)Video

Durvalumab as consolidation treatment for patients with limited-stage small cell lung cancer (ADRIATIC)

June 2024 First Look With ASCO Daily News presents Dr. Julie Gralow, ASCO’s chief medical officer, on…
Osimertinib Improves PFS in EGFR-Mutant, Unresectable, Stage III NSCLC (LAURA)
Osimertinib Improves PFS in EGFR-Mutant, Unresectable, Stage III NSCLC (LAURA)Video

Osimertinib Improves PFS in EGFR-Mutant, Unresectable, Stage III NSCLC (LAURA)

June 2024 First Look With ASCO Daily News presents Dr. Julie Gralow, ASCO’s chief medical…
Adagrasib versus docetaxel for previously treated KRASG12C-mutated locally advanced or metastatic NSCLC (KRYSTAL-12)
Adagrasib versus docetaxel for previously treated KRASG12C-mutated locally advanced or metastatic NSCLC (KRYSTAL-12)Video

Adagrasib versus docetaxel for previously treated KRASG12C-mutated locally advanced or metastatic NSCLC (KRYSTAL-12)

June 2024 First Look With ASCO Daily News presents Dr. Tony Mok on the results of KRYSTAL-12…
CheckMate 67T: subcutaneous versus intravenous nivolumab in ccRCC (CheckMate 67T)
CheckMate 67T: subcutaneous versus intravenous nivolumab in ccRCC (CheckMate 67T)Video

CheckMate 67T: subcutaneous versus intravenous nivolumab in ccRCC (CheckMate 67T)

June 2024 For VJ Oncology Dr. Maria Bourlon for Mexico discusses findings from Phase III…
Dr Jänne on an Exploratory Analysis from FLAURA2 of Baseline ctDNA in EGFR+ NSCLC
Dr Jänne on an Exploratory Analysis from FLAURA2 of Baseline ctDNA in EGFR+ NSCLCVideo

Dr Jänne on an Exploratory Analysis from FLAURA2 of Baseline ctDNA in EGFR+ NSCLC

April 2024 Dr. Pasi Jänne en onderzoekers voerden verdere analyse van FLAURA2 studie uit om…
ESMO 2023 Adjuvant alectinib leidt tot langere DFS bij ALK+ NSCLC
ESMO 2023 Adjuvant alectinib leidt tot langere DFS bij ALK+ NSCLCVideo

ESMO 2023 Adjuvant alectinib leidt tot langere DFS bij ALK+ NSCLC

Oktober 2023 Dr. Ben Solomon presenteerde op ESMO 2023 de resultaten van de ALINA studie…
ESMO 2023 Eerstelijns selpercatinib effectiever dan pembrolizumab-chemotherapie bij RET-positief NSCLC
ESMO 2023 Eerstelijns selpercatinib effectiever dan pembrolizumab-chemotherapie bij RET-positief NSCLCVideo

ESMO 2023 Eerstelijns selpercatinib effectiever dan pembrolizumab-chemotherapie bij RET-positief NSCLC

Oktober 2023 Herbert Loong presenteerde op ESMO 2023 de resultaten van de LIBRETTO-431 studie met…
ESMO 2023 Combinaties met amivantamab effectiever dan chemotherapie bij NSCLC met gemuteerd EGFR
ESMO 2023 Combinaties met amivantamab effectiever dan chemotherapie bij NSCLC met gemuteerd EGFRVideo

ESMO 2023 Combinaties met amivantamab effectiever dan chemotherapie bij NSCLC met gemuteerd EGFR

Oktober 2023 Antonio Passaro presenteerde op ESMO 2023 de resultaten van de MARIPOSA-2 studie waarin…
ESMO 2023 Datopotamab deruxtecan bij gevorderd NSCLC  
ESMO 2023 Datopotamab deruxtecan bij gevorderd NSCLC  Video

ESMO 2023 Datopotamab deruxtecan bij gevorderd NSCLC  

Oktober 2023 Aaron Lisberg presenteerde op ESMO 2023 de resultaten datopotamab deruxtecan bij gevorderd NSLC…
CheckMate 9LA studie – korte uitleg 
CheckMate 9LA studie – korte uitleg Video

CheckMate 9LA studie – korte uitleg 

Deze video vertelt u in minder dan 3 minuten de belangrijkste uitkomsten van de 3…
ESMO 2022 – Highlights IPSOS study
ESMO 2022 – Highlights IPSOS studyVideo

ESMO 2022 – Highlights IPSOS study

ESMO - 2022 - Results from a phase III study of first-line (1L) atezolizumab (atezo)…